Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096100 | 0.84 | — | — | |
| SCHEMBL117341 | 0.77 | GRIN2D (0.32) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL25532857 | 0.74 | GRIN2D (0.31) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL681110 | 0.74 | PHGDH (0.36) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL680630 | 0.74 | GRIN2D (0.31) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL24235929 | 0.74 | GRIN2D (0.31) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL25530735 | 0.74 | GRIN2D (0.31) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL21538284 | 0.74 | — | — | |
| SCHEMBL23509384 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL21161583 | 0.72 | GRIN2D (0.30) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023183768-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023055679-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220315568-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3277690-A1 | SPIROCYCLIC COMPOUNDS | Kalyra Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016161160-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-2870150-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| EP-1523484-A2 | 3-PHENYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004007498-A2 | 3-PHENYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | GRIN2D 4028/4885GRIN3B 3899/4885CHRM2 4793/4885 |
| US-20220315568-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, SARNP | GRIN2D 1020/4885GRIN3B 323/4885CHRM2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.